Siti Nor Fadhlina MİSRON, Zahiruddin OTHMAN, Lukmanul Hakim MİSRON

Anticholinergic delirium superimposed on severe cognitive deficit secondary to benzhexol and flupenthixol decanoate: A dilemma in management

The first and second generation antipsychotics are associated with cognitive impairment through the antidopaminergic and anticholinergic effects. However serious anticholinergic adverse events may occur in susceptible individual, such as being illustrated in this case, even though flupenthixol decanoate has never been reported to cause them. The concomitant use of anticholinergic medication to counter the antidopaminergic side effects may further accentu ate this condition and leads to delirium despite within the therapeutic dosage.

PDF

___

McGlashan TH. The Chestnut Lodge follow-up study. II. Long-term outcome of schizophrenia and the affective disorders. Arch Gen Psychiatry 1984; 41: 586-601.

Ray PG, Meador KJ, Loring DW, Zamrini EW, Yang XH, Buccafusco JJ. Central anticholinergic hypersensitivity in aging. J Geriatr Psychiatry Neurol 1992; 5: 72-77.

Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium – theory, evidence and practice. Br J Clin Pharmacol 2015; 81: 516-524.

Mahapatra J, Quraishi SN, David A, Sampson S, Adams CE. Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders. Cochrane Database of Systematic Reviews 2014; CD001470.

Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006; 148: 565-578.

Burke RE, Fahn S. Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients. Ann Neurol 1985; 18: 35-40.

Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry. 12th ed. West Sussex: Wiley Blackwell 2015.

Ownens DC. Meet the relatives: a reintroduction to the clinical pharmacology of ‘typical’ antipsychotics (Part 2). Adv Psychiatric Treatment 2012; 18: 337- 350.

Rehse M, Bartolovic M, Baum K, Richter D, Weisbrod M, Roesch-Ely D. Influence of antipsychotic and anticholinergic loads on cognitive functions in patients with schizophrenia. Schizophr Res Treatment 2016; 2016: 8213165.

Elie D, Poirier M, Chianetta JM, Durand M, Grégoire CA, Grignon S. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol 2010; 24: 1037-1044.

Meltzer HY, Park S, Kessler R. Cognition, schizophrenia, and the atypical antipsychotic drugs. PNAS 1999; 96: 13591-13593.

Ogino S, Miyamoto S, Miyake N, Yamaguchi N. Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function. Psychiatry Clin Neurosci 2014; 68: 37-49.